Producer
Luye Pharma Group Ltd.
Chinese specialty pharmaceutical group (Yantai, Shandong Province; HKEX: 2186; ~HKD 5B revenue); oncology and central nervous system drug focus with vertically integrated paclitaxel API and finished-dose manufacturing capabilities. Luye produces paclitaxel API at Chinese manufacturing sites and formulates injectable paclitaxel and albumin-bound paclitaxel (nab-paclitaxel, analogous to Abraxane). The company has expanded internationally with European acquisitions (Acino AG in 2014) and supplies paclitaxel products to Asian, European, and emerging-market oncology markets. Luye is among the few Chinese pharmaceutical companies with both upstream API and downstream finished-dose capability for the taxane class.
1
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
1 input Luye Pharma Group Ltd. supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Luye Pharma Group Ltd. makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Oncology (Paclitaxel, Taxanes)
45%Central Nervous System (CNS)
35%Cardiovascular & Other
20%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Did you know2024
Luye Pharma is tracked as a Chinese cancer drug company (oncology supply chain), but through the Adamas acquisition it is now also a US Alzheimer's disease drug company (CNS/neurology supply chain). The same Chinese pharmaceutical group that manufactures paclitaxel for Chinese cancer patients also owns the US commercial rights to an Alzheimer's combination drug (Namzaric) sold in US pharmacies. The oncology API supply chain (Chinese manufacturing) and the US CNS branded drug market are connected through a single Hong Kong-listed Chinese pharma company — a connection that neither US pharmaceutical market analysts nor Chinese oncology supply chain analysts typically model as the same entity.
Luye Pharma Group ↗Origin2023
Luye Pharma Group was founded in 1994 by Liu Dianbo in Yantai, Shandong Province — one of China's key pharmaceutical manufacturing cities on the Bohai Sea coast. Luye built its pharmaceutical foundation on paclitaxel manufacturing (oncology) before diversifying into CNS drugs through the 2018 acquisition of Adamas Pharmaceuticals (Emeryville, California), gaining rights to Namzaric (memantine+donepezil for Alzheimer's disease) and the US commercialization infrastructure. The acquisition transformed a Chinese oncology drug manufacturer into a company with a US CNS drug franchise, listing on Hong Kong Stock Exchange to access international capital.
Luye Pharma Group ↗